Company Profile

Established in 2003, Coronis Partners invested in a portfolio of ten highly selected Biotechnology and Biopharmaceutical companies, out of which five reached public markets (BiondVax Ltd., Evogene Ltd., Rosetta Genomics Ltd., Prolor Biotech Ltd. and Glycominds Ltd.).
As of 2012 Coronis operates as a specialty pharma company, focusing on  the development of a pipeline of in-licensed de-risked small molecules  for the treatment of Central Nervous System and Ophthalmology diseases.

Daronet Web Building